Literature DB >> 26718971

The pathogenesis and treatment of cardiac atrophy in cancer cachexia.

Kate T Murphy1.   

Abstract

Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal muscle mass associated with significant functional impairment. In addition to a loss of skeletal muscle mass and function, many patients with cancer cachexia also experience cardiac atrophy, remodeling, and dysfunction, which in the field of cancer cachexia is described as cardiac cachexia. The cardiac alterations may be due to underlying heart disease, the cancer itself, or problems initiated by the cancer treatment and, unfortunately, remains largely underappreciated by clinicians and basic scientists. Despite recent major advances in the treatment of cancer, little progress has been made in the treatment of cardiac cachexia in cancer, and much of this is due to lack of information regarding the mechanisms. This review focuses on the cardiac atrophy associated with cancer cachexia, describing some of the known mechanisms and discussing the current and future therapeutic strategies to treat this condition. Above all else, improved awareness of the condition and an increased focus on identification of mechanisms and therapeutic targets will facilitate the eventual development of an effective treatment for cardiac atrophy in cancer cachexia.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  cancer cachexia; cardiac atrophy; cardiac cachexia; cardiac dysfunction; cardiomyopathy

Mesh:

Year:  2015        PMID: 26718971     DOI: 10.1152/ajpheart.00720.2015

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  38 in total

1.  Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat.

Authors:  Peter J Esau; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Korynne S Rollins; Dryden R Baumfalk; David C Poole; Timothy I Musch; Bradley J Behnke; Steven W Copp
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.

Authors:  Thiago Ferreira de Souza; Thiago Quinaglia A C Silva; Felipe Osorio Costa; Ravi Shah; Tomas G Neilan; Lício Velloso; Wilson Nadruz; Fabricio Brenelli; Andrei Carvalho Sposito; Jose Roberto Matos-Souza; Fernando Cendes; Otávio Rizzi Coelho; Michael Jerosch-Herold; Otavio Rizzi Coelho-Filho
Journal:  JACC Cardiovasc Imaging       Date:  2018-08

3.  Cardiac Atrophy and Heart Failure In Cancer.

Authors:  Mark Sweeney; Angela Yiu; Alexander R Lyon
Journal:  Card Fail Rev       Date:  2017-04

4.  Effects of high-intensity training on prostate cancer-induced cardiac atrophy.

Authors:  Dryden R Baumfalk; Alexander B Opoku-Acheampong; Jacob T Caldwell; Alec L E Butenas; Andrew G Horn; Olivia N Kunkel; Steven W Copp; Carl J Ade; Timothy I Musch; Bradley J Behnke
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

5.  VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.

Authors:  Markus Räsänen; Joni Degerman; Tuuli A Nissinen; Ilkka Miinalainen; Risto Kerkelä; Antti Siltanen; Janne T Backman; Eero Mervaala; Juha J Hulmi; Riikka Kivelä; Kari Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 6.  Effects of ionizing radiation on the heart.

Authors:  Marjan Boerma; Vijayalakshmi Sridharan; Xiao-Wen Mao; Gregory A Nelson; Amrita K Cheema; Igor Koturbash; Sharda P Singh; Alan J Tackett; Martin Hauer-Jensen
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-10       Impact factor: 5.657

Review 7.  Cardiac Complications: The Understudied Aspect of Cancer Cachexia.

Authors:  Vivek Bora; Bhoomika Patel
Journal:  Cardiovasc Toxicol       Date:  2022-02-16       Impact factor: 3.231

8.  Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia.

Authors:  Vivek R Bora; Dhruv Gohel; Rajesh Singh; Bhoomika M Patel
Journal:  Mol Cell Biochem       Date:  2022-09-13       Impact factor: 3.842

9.  Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.

Authors:  James T Thackeray; Stefan Pietzsch; Britta Stapel; Melanie Ricke-Hoch; Chun-Wei Lee; Jens P Bankstahl; Michaela Scherr; Jörg Heineke; Gesine Scharf; Arash Haghikia; Frank M Bengel; Denise Hilfiker-Kleiner
Journal:  JCI Insight       Date:  2017-05-18

10.  Cancer-induced Cardiac Atrophy Adversely Affects Myocardial Redox State and Mitochondrial Oxidative Characteristics.

Authors:  David E Lee; Jacob L Brown; Megan E Rosa-Caldwell; Richard A Perry; Lemuel A Brown; Wesley S Haynie; Tyrone A Washington; Michael P Wiggs; Narasimhan Rajaram; Nicholas P Greene
Journal:  JCSM Rapid Commun       Date:  2020-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.